Galena Biopharma (GALE) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Galena Biopharma Reports Fourth Quarter and Year End 2015 Financial Results and Provides a Corporate Update
March 10, 2016 4:10 PM ESTTwo Key Milestones in the NeuVax (nelipepimut-S) Phase 3, PRESENT Clinical Trial Expected in 1H, 2016Webcast and conference call scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T.
SAN RAMON, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today reported its financial results for the quarter and year ended December 31, 2015. Â
2016 is poised to be a critical year for Galena as... More
